Next Generation Sequencinggg
NGS techniques have been used for high-throughput whole viral genome sequencing, such as sequencing of new influenza viruses, for detection of viral
genome variability and
evolution within the host, such as investigation of human
immunodeficiency virus and human
hepatitis C virus quasispecies, and monitoring. NGS can be used to sequence entire genomes or constrained to specific areas of interest, including all 22 000 coding genes (a whole exome) or small numbers of individual genes. Example of next generation sequencing (NGS) raw data-BRAF V600E mutation in melanoma. To perform Sanger Sequencing, you add your primers to a solution containing the genetic
information to be sequenced, then divide up the solution into four
PCR reactions. Each reaction contains a with dNTP mix with one of the four nucleotides substituted with a ddNTP (A, T, G, and C ddNTP groups). Advantages of NGS include: Higher sensitivity to detect low-frequency variants. Faster turnaround time for high sample volumes. Comprehensive genomic coverage. Next generation sequencing (NGS) strategies for the genetic testing of myopathies. ... This brings the genetic testing procedure to a higher level of complexity. The positive aspect is the ease to cope with the complex diagnosis of genetically heterogeneous disorders and to identify novel disease genes
High Impact List of Articles
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
The challenges of dengue drug discovery and development
Feng Gu, Pei-Yong Shi
Editorial: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Graham W Warren
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
An update on clinical trials in Charcot-Marie-Tooth Disease
Davide Pareyson & Giuseppe Piscosquito
Commentary: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
Relevant Topics in Clinical